



## Preferred Drug List

### NEW DRUG REVIEW

**Proprietary Name:** Viibryd™

**Common Name:** vilazodone

**PDL Category:** Antidepressants- Selected SSRIs

<u>Comparable Products</u>	<u>Preferred Drug List Status</u>
Fluoxetine	Preferred
Lexapro®	Preferred
Paroxetine	Preferred
Sertraline	Preferred

#### Summary

**Indications and Usage:** Indicated for the treatment of major depressive disorder (MDD) in adults.<sup>1</sup>

**Mechanism of Action:** Potentiates serotonergic activity by inhibiting the central nervous system (CNS) neuronal uptake of serotonin (5HT). Vilazodone is also a partial agonist at serotonergic 5-HT<sub>1A</sub> receptors, in which the effects of this are unknown.<sup>1</sup>

**Dosage Forms:** Tablets: 10mg, 20mg and 40mg

**Recommended Dosage:** Recommended dose is 40mg once daily taken with food, with dose titration of 10mg once daily for 7 days, followed by 20mg once daily for 7 days to target dose.<sup>1</sup>

**Common Adverse Drug Reactions:** Diarrhea, nausea, vomiting, insomnia.<sup>1</sup>

**Contraindications:** Do not use concomitantly with an MAOI or within 14 days of stopping or starting an MAOI.<sup>1</sup>

**Manufacturer:** Forest Pharmaceuticals, Inc.

**Analysis:** Viibryd™ is a new dual-acting serotonergic antidepressant. Viibryd™ was compared only to placebo in the clinical trials used to gain FDA approval. In the 8 week clinical trials, Viibryd™ was superior to placebo in reducing depressive symptoms as measured by the mean change from baseline in the Montgomery-Asburg Depression Rating Scale (MADRS). Viibryd™ has not been shown to be clinically superior to current treatment options and has an increased risk of gastrointestinal (GI) side effects. Preferred alternatives appear on the Preferred Drug List, which have similar clinical efficacy, are more cost effective, and have a pediatric indication. Therefore, it is recommended that Viibryd™ be added to the Preferred Drug List as a non-preferred drug.

**IME Recommendation:**

<input type="checkbox"/> Preferred Drug	<input type="checkbox"/> Recommended Drug
<input checked="" type="checkbox"/> Non-Preferred Drug	<input type="checkbox"/> Non-Recommended Drug
<input type="checkbox"/> Non-Preferred Drug with Conditions	

1. Viibryd™ [package insert]. St. Louis, MO: Forest Pharmaceuticals, Inc.; 2011.